SUPPORTING INFORMATION: Figure S1. Literature search strategy, inclusion and exclusion criteria employed to arrive at the articles used in this study.
Figure S2. The isolation rate of Gram-negative bacterial species obtained from infants and pregnant women per country.
Figure S3. Mortality rates associated with carbapenem resistance in infants per country.
Figure S4. The count and isolation rates of Gram-negative bacterial species obtained from pregnant women and infants per country.
Figure S5. The count of Gram-negative bacteria clones infecting or colonizing infants and pregnant women per country.
Figure S6. Carbapenem and polymyxin resistance rates in Gram-negative bacteria isolated from infants and pregnant women.
Figure S7. Carbapenemases detected in Gram-negative bacteria per country.
Figure S8. Risk factors associated with carbapenem and polymyxin-resistant Gram-negative bacteria in neonates and pregnant women.
Table S1. Data on the epidemiology, risk factors, clinical outcomes, resistance mechanisms and rates, and the prevalence of carbapenem-resistant Gram-negative bacteria infecting or colonizing infants.
Table S2. Data on the epidemiology, risk factors, clinical outcomes, resistance mechanisms and rates, and the prevalence of carbapenem-resistant Gram-negative bacteria infecting or colonizing pregnant women.
Table S3. Data on the epidemiology, risk factors, clinical outcomes, resistance mechanisms and rates, and the prevalence of polymyxin-resistant Gram-negative bacteria infecting or colonizing infants and pregnant women.
Table S4. Statistical analyses of the pooled data showing association between age, species, countries, resistance mechanisms, clones, risk factors, and mortalities.
